Developing cellular therapies is not straightforward. This Perspective summarizes the experience of a group of academic stem cell investigators working in different clinical areas and aims to share insight into what we wished we knew before starting. These include (1) choosing the stem cell line and assessing the genome of both the starting and final product, (2) familiarity with GMP manufacturing, reagent validation, and supply chain management, (3) product delivery issues and the additional regulatory challenges, (4) the relationship between clinical trial design and preclinical studies, and (5) the market approval requirements, pathways, and partnerships needed.
Lessons learnt, and still to learn, in first in human stem cell trials / Barker, R. A.; Carpenter, M.; Jamieson, C. H. M.; Murry, C. E.; Pellegrini, G.; Rao, R. C.; Song, J.. - In: STEM CELL REPORTS. - ISSN 2213-6711. - 18:8(2023), pp. 1599-1609. [10.1016/j.stemcr.2022.11.019]
Lessons learnt, and still to learn, in first in human stem cell trials
Pellegrini G.;
2023
Abstract
Developing cellular therapies is not straightforward. This Perspective summarizes the experience of a group of academic stem cell investigators working in different clinical areas and aims to share insight into what we wished we knew before starting. These include (1) choosing the stem cell line and assessing the genome of both the starting and final product, (2) familiarity with GMP manufacturing, reagent validation, and supply chain management, (3) product delivery issues and the additional regulatory challenges, (4) the relationship between clinical trial design and preclinical studies, and (5) the market approval requirements, pathways, and partnerships needed.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2213671122005525-main.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
419.47 kB
Formato
Adobe PDF
|
419.47 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
